Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 149
- Registration Number
- NCT03361748
- Locations
- 🇺🇸
Local Institution - 103, Atlanta, Georgia, United States
🇺🇸Local Institution - 104, Dallas, Texas, United States
🇪🇸Local Institution - 702, Badalona (Barcelona), Spain
A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 145
- Registration Number
- NCT03342404
- Locations
- 🇬🇷
Local Institution - 102, Athens, Greece
🇺🇸Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122
- Conditions
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 81
- Registration Number
- NCT03340662
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 34
- Registration Number
- NCT03337022
- Locations
- 🇨🇦
Innovaderm Research, Montreal, Quebec, Canada
🇺🇸TKL Research, Fair Lawn, New Jersey, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis
- Conditions
- Interventions
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 8
- Registration Number
- NCT03324503
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine - Baltimore, Baltimore, Maryland, United States
🇳🇱Catharina Ziekenhuis, Eindhoven, Netherlands
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 62
- Registration Number
- NCT03310619
- Locations
- 🇺🇸
Local Institution - 015, Omaha, Nebraska, United States
🇺🇸Local Institution - 016, Philadelphia, Pennsylvania, United States
🇺🇸Local Institution - 011, Duarte, California, United States
Radiolabeled Study of CC-220 in Healthy Male Subjects
- First Posted Date
- 2017-09-27
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 6
- Registration Number
- NCT03294603
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 31
- Registration Number
- NCT03290443
- Locations
- 🇺🇸
New Orleans Center of Clinical Research, Knoxville, Tennessee, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 600
- Registration Number
- NCT03288974
- Locations
- 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 35
- Registration Number
- NCT03283202
- Locations
- 🇪🇸
Hospital Universitario Virgen Del Rocio, Sevilla, Spain
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Washington University, Saint Louis, Missouri, United States